[Combined effect of gemcitabine and lomustine in mice with intracranial transplanted lymphosarcoma LIO-1]

Autor:	A N, Stukov, L V, Filatova, M L, Gershanovich, T Iu, Semiglazova, A A, Tarasenkova, D Kh, Latinova, S F, Vershinina, N I, Zargarova
Rok vydání:	2012
Předmět:	Male Antimetabolites Antineoplastic Maximum Tolerated Dose Lymphoma Non-Hodgkin Administration Oral Drug Synergism Deoxycytidine Survival Analysis Gemcitabine Mice Lomustine Antineoplastic Combined Chemotherapy Protocols Animals Antineoplastic Agents Alkylating Injections Intraperitoneal
Zdroj:	Voprosy onkologii. 58(3)
ISSN:	0507-3758
Popis:	SHR mice with intracranial transplanted lymphosarcoma LIO-1 received a single intraperitoneal gemcitabine injection in maximal tolerated dose of 25 mg/kg or single maximal tolerated oral dose of lomustine, 50 mg/kg. Compared to control group gemcitabine injection increased the mice lifespan 1.4-fold (p0,01) and oral lomustine 1.6-fold (p0,01). The median lifespan of the mice receiving both gemcitabine and lomustine in maximal dose underwent a significant 3.3-fold increase (p0,01) compared to controls (2.4-fold compared to gemcitabine and 2.1-fold compared to lomustine group). Combined therapy didn't cause an increase of toxicity.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::e20143bf6abb0a44992d61f5160d2aa4 https://pubmed.ncbi.nlm.nih.gov/22888657 Zobrazit plný text záznamu